Design of the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial
References (139)
- et al.
Assessment of screening for prostate cancer using the digital rectal examination
J Urol
(1989) - et al.
Clinical application of transrectal ultrasonography and prostate specific antigen in the search for prostate cancer
J Urol
(1988) - et al.
Adenocarcinoma of the prostate: Results of routine urological screening
J Urol
(1984) - et al.
Impact of routine screening for adenocarcinoma of the prostate on the stage distribution
J Urol
(1987) - et al.
Case-control study of screening for prostatic cancer by digital rectal examinations
Lancet
(1991) - et al.
Comparison of digital examination and transrectal ultrasonography for the diagnosis of prostatic cancer
J Urol
(1986) - et al.
How accurate is the index finger? A comparison of digital and ultrasound examination of the prostatic nodule
Clin Radiol
(1988) - et al.
The use of transrectal prostatic ultrasonography in the evaluation of patients with prostatic carcinoma
J Urol
(1989) - et al.
The value of serum prostate specific antigen determinations before and after radical prostatectomy
J Urol
(1989) - et al.
Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy
J Urol
(1988)
The clinical usefulness of prostate specific antigen: Update, 1994
J Urol
(1994)
Screening for prostatic carcinoma with prostate specific antigen
J Urol
(1992)
Prostate specific antigen density: A means of distinguishing benign prostatic hypertrophy and prostate cancer
J Urol
(1992)
Volume adjustment for intermediate prostate-specific antigen values in a screening population
Eur J Cancer
(1995)
Measurement of prostate specific antigen and gamma-seminoprotein ratio: A new means of distinguishing benign prostatic hyperplasia and prostate cancer
J Urol
(1993)
Significance of different molecular forms of serum PSA. The free, non-complexed form of PSA versus that complexes to alpha 1-antichymotrypsin
Urol Clin North Am
(1993)
The value of screening tests in the detection of prostate cancer. Part I: Results of a retrospective evaluation of 1726 men
Urology
(1995)
Determination of the “reflex range” and appropriate cutpoints for percent free prostate-specific antigen in 413 men referred for prostatic evaluation using the AxSYM system
Urology
(1997)
Natural history of localised prostatic cancer. A population-based study in 223 untreated patients
Lancet
(1989)
Histopathology of prostate cancer: Prediction of malignant behavior and correlation with ultrasonography
Urology
(1989)
Should Medicare provide reimbursement for prostate-specific antigen testing for early detection of prostate cancer? Part IV: Estimating the risks and benefits of an early detection program
Urology
(1995)
Acritique of the decision analysis for clinically localized prostate cancer
J Urol
(1994)
Population-based study of long-term survival in patients with clinically localised prostate cancer
Lancet
(1997)
Physiological variation of serum prostate specific antigen in the 4.0 to 10.0 ng./ml. range in male volunteers
J Urol
(1996)
Evaluating periodic multiphasic health check-ups: A controlled trial
J Chronic Dis
(1979)
Multiphasic health checkup evaluation: A 16-year follow-up
J Chronic Dis
(1986)
Screening for early lung cancer. Results of the Memorial Sloan-Kettering study in New York
Chest
(1984)
Survival benefits of x-ray screening for lung cancer after bias adjustments
Computers and Mathematics with Applications
(1989)
Randomised controlled trial of faecal-occult-blood screening for colorectal cancer
Lancet
(1996)
Randomized study of screening for colorectal cancer with faecal-occult-blood test
Lancet
(1996)
Sigmoidoscopy and mortality from colorectal cancer: The Kaiser Permanente Multiphasic Evaluation Study
J Clin Epidemiol
(1988)
Cancer statistics, 1989
CA Cancer J Clin
(1989)
(2000)
Adjuvant oral alkylating chemotherapy in patients with stage I epithelial ovarian cancer
Cancer
(1989)
Cancer of the prostate gland. Results of early diagnosis and therapy undertaken for cure of the disease
JAMA
(1971)
Evaluation of annual examinations in the detection of cancer
JAMA
(1960)
Early detection of prostate cancer by routine screening
JAMA
(1984)
The relationship of prostate-specific antigen to digital rectal examination and transrectal ultrasonography. Findings of the American Cancer Society National Prostate Cancer Detection Project
Cancer
(1992)
Detection and diagnosis of prostatic cancer
Presentation and clinical course of patients ultimately succumbing to carcinoma of the prostate
Scand J Urol Nephrol
(1991)
Editorial comment
Progress and problems in screening for carcinoma of the prostate
World J Surg
(1989)
Prostate cancer: Comparison of transrectal US and digital rectal examination for screening
Radiology
(1988)
Hypoechoic lesions of the prostate: Clinical relevance of tumor size, digital rectal examination, and prostate-specific antigen
Radiology
(1989)
Transrectal US of the prostate: Is the technology leading the science?
Radiology
(1988)
Early prostate cancer: Diagnostic costs of screening transrectal US and digital rectal examination
Radiology
(1988)
Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate
N Engl J Med
(1987)
Early detection of prostate cancer. Part 1: Prior probability and effectiveness of tests. The American College of Physicians
Ann Intern Med
(1997)
Measurement of prostate-specific antigen in serum as a screening test for prostate cancer
New Engl J Med
(1991)
Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease
JAMA
(1992)
Cited by (831)
A metabolomic investigation of serum perfluorooctane sulfonate and perfluorooctanoate
2023, Environment InternationalDairy product consumption and lung cancer risk: A prospective analysis
2023, Clinical Nutrition ESPENA blood-based metabolomic signature predictive of risk for pancreatic cancer
2023, Cell Reports Medicine
- 1
Deceased.
- 2
Retired.
- 3
A roster of the project team appears in the lead paper of this supplement. Other participants in early design considerations for this trial included former National Cancer Institute investigators David P. Byar (deceased) and Charles R. Smart (retired).
Address reprint requests to: Dorothy Sullivan, Early Detection Research Group, Division of Cancer Prevention, National Cancer Institute, EPN 330, 6130 Executive Blvd., Bethesda, MD 20892-7346.
Copyright © 2000 Published by Elsevier Inc.